These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 29986403)

  • 21. Stable amorphous solid dispersions of fenofibrate using hot melt extrusion technology: Effect of formulation and process parameters for a low glass transition temperature drug.
    Kallakunta VR; Sarabu S; Bandari S; Batra A; Bi V; Durig T; Repka MA
    J Drug Deliv Sci Technol; 2020 Aug; 58():. PubMed ID: 32905375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coamorphous Loratadine-Citric Acid System with Enhanced Physical Stability and Bioavailability.
    Wang J; Chang R; Zhao Y; Zhang J; Zhang T; Fu Q; Chang C; Zeng A
    AAPS PharmSciTech; 2017 Oct; 18(7):2541-2550. PubMed ID: 28224393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Preparation and Evaluation of Co-amorphous Formulations of Telmisartan-Amino Acids as a Potential Method for Solubility and Dissolution Enhancement.
    Khanfar M; Al-Remawi M; Al-Akayleh F; Hmouze S
    AAPS PharmSciTech; 2021 Mar; 22(3):112. PubMed ID: 33748914
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Co amorphous valsartan nifedipine system: Preparation, characterization, in vitro and in vivo evaluation.
    Lodagekar A; Chavan RB; Mannava MKC; Yadav B; Chella N; Nangia AK; Shastri NR
    Eur J Pharm Sci; 2019 Nov; 139():105048. PubMed ID: 31446077
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of Phase Separation Propensity for Amorphous Spray Dried Dispersions.
    McNamara D; Yin S; Pan D; Crull G; Timmins P; Vig B
    Mol Pharm; 2017 Feb; 14(2):377-385. PubMed ID: 28068097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spray drying of poorly soluble drugs from aqueous arginine solution.
    Ojarinta R; Lerminiaux L; Laitinen R
    Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
    Ghebremeskel AN; Vemavarapu C; Lodaya M
    Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hot melt extrusion (HME) for amorphous solid dispersions: predictive tools for processing and impact of drug-polymer interactions on supersaturation.
    Sarode AL; Sandhu H; Shah N; Malick W; Zia H
    Eur J Pharm Sci; 2013 Feb; 48(3):371-84. PubMed ID: 23267847
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of stability-enhanced ternary solid dispersions via combinations of HPMCP and Soluplus
    Albadarin AB; Potter CB; Davis MT; Iqbal J; Korde S; Pagire S; Paradkar A; Walker G
    Int J Pharm; 2017 Oct; 532(1):603-611. PubMed ID: 28923766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Co-amorphous solid dispersion systems of lacidipine-spironolactone with improved dissolution rate and enhanced physical stability.
    Wang Z; Sun M; Liu T; Gao Z; Ye Q; Tan X; Hou Y; Sun J; Wang D; He Z
    Asian J Pharm Sci; 2019 Jan; 14(1):95-103. PubMed ID: 32104442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preparation, characterization and in vitro/vivo evaluation of tectorigenin solid dispersion with improved dissolution and bioavailability.
    Shuai S; Yue S; Huang Q; Wang W; Yang J; Lan K; Ye L
    Eur J Drug Metab Pharmacokinet; 2016 Aug; 41(4):413-22. PubMed ID: 25669445
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-amorphous palbociclib-organic acid systems with increased dissolution rate, enhanced physical stability and equivalent biosafety.
    Zhang M; Xiong X; Suo Z; Hou Q; Gan N; Tang P; Ding X; Li H
    RSC Adv; 2019 Jan; 9(7):3946-3955. PubMed ID: 35518078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of co-amorphous carvedilol-maleic acid system prepared by solvent evaporation.
    Furuishi T; Sato-Hata N; Fukuzawa K; Yonemochi E
    Pharm Dev Technol; 2023; 28(3-4):309-317. PubMed ID: 36946594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hard Gelatin Capsules Containing Hot Melt Extruded Solid Crystal Suspension of Carbamazepine for improving dissolution: Preparation and
    Narala S; Komanduri N; Nyavanandi D; Youssef AAA; Mandati P; Alzahrani A; Kolimi P; Narala N; Repka MA
    J Drug Deliv Sci Technol; 2023 Apr; 82():. PubMed ID: 37124158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solid state characterization of azelnidipine-oxalic acid co-crystal and co-amorphous complexes: The effect of different azelnidipine polymorphs.
    Pan Y; Pang W; Lv J; Wang J; Yang C; Guo W
    J Pharm Biomed Anal; 2017 May; 138():302-315. PubMed ID: 28237872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
    Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
    J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development of hot melt co-formulated antimalarial solid dispersion system in fixed dose form (ARLUMELT): Evaluating amorphous state and in vivo performance.
    Fule R; Dhamecha D; Maniruzzaman M; Khale A; Amin P
    Int J Pharm; 2015 Dec; 496(1):137-56. PubMed ID: 26471056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-former selection for co-amorphous drug-amino acid formulations.
    Kasten G; Löbmann K; Grohganz H; Rades T
    Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Co-amorphous Systems of Sinomenine with Platensimycin or Sulfasalazine: Physical Stability and Excipient-Adjusted Release Behavior.
    Chen X; Li D; Zhang H; Duan Y; Huang Y
    Mol Pharm; 2022 Nov; 19(11):4370-4381. PubMed ID: 36251509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.